Your session is about to expire
← Back to Search
5-HT3 Receptor Antagonist
Granisetron Patch vs Ondansetron for Nausea and Vomiting
Phase 4
Recruiting
Led By Karen Sweiss, PharmD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.
No vomiting ≤ 24 hours prior to registration
Must not have
Patients with a history of long QT syndrome or Torsade de Pointes
Concurrent use of amifostine
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial is testing a new drug to see if it is more effective at reducing CINV in patients undergoing an HSCT than the current standard of care.
Who is the study for?
This trial is for adults aged 18-75 undergoing stem cell transplant and chemotherapy, who haven't vomited in the last 24 hours or taken certain antipsychotic drugs recently. It's not for those allergic to granisetron or ondansetron, with a history of specific heart rhythm problems, or using amifostine.Check my eligibility
What is being tested?
The study compares two anti-nausea treatments in patients receiving stem cell transplants: a granisetron patch versus ondansetron. The goal is to see which one better prevents nausea and vomiting caused by chemotherapy.See study design
What are the potential side effects?
Possible side effects include skin reactions at the patch site for granisetron, headaches, constipation, and potential heart rhythm changes. Ondansetron can cause headaches, dizziness, constipation as well as rare heart-related side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 75 years old and will receive a stem cell transplant.
Select...
I have not vomited in the last 24 hours.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of long QT syndrome or Torsade de Pointes.
Select...
I am currently taking amifostine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy/Safety of Transdermal Granisetron for Prevention of CINV
Secondary outcome measures
Efficacy/Safety of Ondansetron and Transdermal Granisetron for Prevention of CINV
Efficacy/Safety of Ondansetron for Prevention of CINV
Trial Design
2Treatment groups
Active Control
Group I: Arm 1Active Control2 Interventions
ARM 1 -transdermal granisetron plus intravenous dexamethasone
Group II: ARM 2Active Control2 Interventions
ARM 2 -intravenous ondansetron plus intravenous dexamethasone
Find a Location
Who is running the clinical trial?
University of Illinois at ChicagoLead Sponsor
618 Previous Clinical Trials
1,563,734 Total Patients Enrolled
Karen Sweiss, PharmD3.520 ReviewsPrincipal Investigator - University of Illinois at Chicago
University of Illinois at Chicago
1Patient Review
The long wait time for an appointment was only the beginning of my issues with Dr. Sweiss. I waited almost two hours for her to show up to the office, which her own staff says is typical. This is completely unacceptable. Her disorganization and lack of readiness for my appointment led to accomplishing absolutely nothing. She ordered a test which has already been done and then had the resident let me know that she wanted to follow up in 3 to 6 months. I'm not sure what the follow up was for since she did absolutely nothing during this appointment time. The incompetence, lack of professionalism, and lack of compassion shown by UI
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 75 years old and will receive a stem cell transplant.I am not on long-term antipsychotic drugs but may take them for nausea.I haven't taken any antipsychotic medications like risperidone or quetiapine in the last 30 days.I have not vomited in the last 24 hours.I have a history of long QT syndrome or Torsade de Pointes.I am currently taking amifostine.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 1
- Group 2: ARM 2
Awards:
This trial has 3 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger